adenine and Cough
adenine has been researched along with Cough in 2 studies
Cough: A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Aldana, G | 1 |
| Jimenez, CA | 1 |
| Moran, C | 1 |
| Byrd, JC | 1 |
| Brown, JR | 1 |
| O'Brien, S | 1 |
| Barrientos, JC | 1 |
| Kay, NE | 1 |
| Reddy, NM | 1 |
| Coutre, S | 1 |
| Tam, CS | 1 |
| Mulligan, SP | 1 |
| Jaeger, U | 1 |
| Devereux, S | 1 |
| Barr, PM | 1 |
| Furman, RR | 1 |
| Kipps, TJ | 1 |
| Cymbalista, F | 1 |
| Pocock, C | 1 |
| Thornton, P | 1 |
| Caligaris-Cappio, F | 1 |
| Robak, T | 1 |
| Delgado, J | 1 |
| Schuster, SJ | 1 |
| Montillo, M | 1 |
| Schuh, A | 1 |
| de Vos, S | 1 |
| Gill, D | 1 |
| Bloor, A | 1 |
| Dearden, C | 1 |
| Moreno, C | 1 |
| Jones, JJ | 1 |
| Chu, AD | 1 |
| Fardis, M | 1 |
| McGreivy, J | 1 |
| Clow, F | 1 |
| James, DF | 1 |
| Hillmen, P | 1 |
Clinical Trials (7)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
| A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707] | Phase 3 | 391 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
| Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia[NCT03755947] | Phase 2 | 3 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895] | 40 participants (Actual) | Observational | 2017-07-21 | Active, not recruiting | |||
| Expression of CD19 Complex in Lymphoproliferative Disorders[NCT04734470] | 92 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
| Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Ibrutinib Plus Rituximab | 0 |
OS (Overall Survival)
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 65.1 |
| Ibrutinib (Arm B) | 67.7 |
Overall Response Rate (ORR) by Independent Review Committee (IRC)
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab (Arm A) | 4.1 |
| Ibrutinib (Arm B) | 42.6 |
Overall Response Rate (ORR) by Investigator
Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab (Arm A) | 22.4 |
| Ibrutinib (Arm B) | 87.7 |
PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 8.1 |
| Ibrutinib (Arm B) | NA |
Progression Free Survival (PFS) by Investigator With up to 6 Years of Study Follow-up
Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 8.1 |
| Ibrutinib (Arm B) | 44.1 |
Rate of Sustained Hemoglobin and Platelet Improvement
Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Hgb Improvement in patient with baseline anemia | Platelet improvement in baseline thrombocytopenia | |
| Ibrutinib (Arm B) | 69.7 | 78.4 |
| Ofatumumab (Arm A) | 32.6 | 9.4 |
Trials
1 trial available for adenine and Cough
| Article | Year |
|---|---|
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Topics: Adenine; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal | 2014 |
Other Studies
1 other study available for adenine and Cough
| Article | Year |
|---|---|
Unusual cause of sinusitis and cough.
Topics: Adenine; Biopsy; Cough; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Midd | 2018 |